← Back to headlines
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics
H.C. Wainwright has reiterated its 'Buy' rating for Allogene Therapeutics (ALLO), indicating a positive outlook on the company's stock.
23 Apr, 07:30 — 23 Apr, 07:30
Sources
Showing 1 of 1 sources
